LDS/Medical Tests/Cytochrome P450 1A2 (CYP1A2) Genotyping

Cytochrome P450 1A2 (CYP1A2) Genotyping

The cytochrome P450 (CYP450) enzymes metabolize the majority of drugs as well as organic compounds in our body. Most of CYP450 enzyme family members are expressed in the liver. The expression level of different CYP enzymes varies. Some of the highly expressed CYP enzymes in the liver include CYPs 1A2, 3A4, 2C9, 2C8, and 2E1. The expression levels and/or activities of CYPs of each individual are affected by factors like genetic polymorphism, disease condition, and inducing or inhibitory chemicals. Accumulative evidences have shown that genetic polymorphisms of different CYP genes, which largely depend on ethnicity, are clinically important regarding drug dosing, drug efficacy, and adverse drug reactions (ADRs).

CYP1A2 is a CYP family protein with 55 amino acid residues, and a molecular mass of 58,294 Da. CYP1A2 is an abundant CYP450 enzyme in the liver, expressing 5-6 times higher than CYP2D6. Among over 100 substrates of CYP1A2, many of them are clinically important drugs, such as clozapine, tacrine, benzopyrene, and aflatoxin b1. CYP1A2 substrates constitute 9% of all prescription drugs. Caffeine is metabolized by CYP1A2 and its role in myocardial risk has been studied with regard to CYP1A2 metabolism. Both genetic and environmental factors are important for CYP1A2 in human liver. Different studies estimate that genetic variation contributes 33% to 75% of total CYP1A2 activity. Other environmental factors, such as the induction or inhibition chemicals make up the remaining differences of CYP1A2 function. A predominant role of CYP1A2 is to activate toxic xenobiotics. Many epidemiological reports have shown the role of CYP1A2 in metabolism of procarcinogens and cancer risk.

To date, more than 21 variants have been reported for CYP1A2. Genetic variations contribute to 40% variability in CYP1A2 gene expression and 60% of its enzymatic activity measured by caffeine metabolism. CYP1A2 variations \*1C and \*1F in its promoter region can affect its inducibility. A coding region variation \*6 is found to alter its enzyme activity. However, few variants could fully explain the expression or inducibility of CYP1A2 gene.

  • Determining therapeutic strategy for drugs metabolized by CYP1A2
  • Monitor and manage fluvoxamine and olanzapine drug therapy
  • As an aid to estimate metabolism of procarcinogens and cancer risks

Increased in:

  • CYP1A2 *1F (-163C>A) has higher inducibility in smokers or patients taking omeprazole.

Decreased in:

  • Decreased expression or enzymatic activity of CYP1A2 is seen in \*1C, \*1K, \*3, \*4, \*6, \*7, \*8, \*11, \*15, and \*16.

Drug Substrates:
caffeine, clopidogrel, theophylline, Coumadin (warfarin), Acetaminophen, amitriptyline, clomipramine, clozapine, cyclobenzaprine, estradiol, fluvoxamine, haloperidol, imipramine, mexiletine, naproxen, olanzapine, ondansetron, phenacetin, propranolol, riluzole, ropivacaine, tacrine, tizanidine, verapamil, zileuton, and zolmitriptan

Drug Inhibitor:
fluvoxamine

Drug Inducer:
albendazole, lansoprazole, omeprazole, primaquine

CYP1A2 \*1A/\*1A (Normal metabolizer)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Acceptable specimens include buccal swab and peripheral blood (EDTA) or saliva.

Buccal swabs can be collected by rubbing the inside of the cheeks with a swab (similar to a Q-tip and generally 4 swabs). The swabs are transported to the laboratory in a liquid medium (see manufacturer guidelines for details) or dry swab).

Peripheral blood is collected through venipuncture. A minimum of 5-10 ml of whole blood is required. The specimen is collected in a lavender top (EDTA) tube.

Stability (Blood specimens):

  • Ambient: 5 days
  • Refrigerated: 7 days

Metabolism of therapeutic drugs could be monitored by LC-MS or other methods to better assess ADR or drug dosing.

Genotyping of other CYP enzymes such as CYP2D6, CYP2C19, CYP2C9, and CYP3A4 are recommended to assess metabolism rates of certain drugs.

3-7 days

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login

AAPS J. 2009 Sep;11(3):481-94. [PMID: 19590965]
IARC Sci Publ. 1999;(148):173-95. [PMID: 10493258]
Drug Metab Rev. 2010 May;42(2):268-354. [PMID: 19961320]
Pharmacogenomics. 2008 May;9(5):625-37. [PMID: 18466106]
Pharmacol Ther. 2013 Apr;138(1):103-41. [PMID: 23333322]
Pharmacogenetics. 1999 Jun;9(3):367-75. [PMID: 10471069]
Arch Pharm Res. 2011 Nov;34(11):1799-816. [PMID: 22139682]